BRD4 and acute lymphoblastic leukemia: Accordingly, BET inhibitors which release BRD4 from chromatin downregulate expression of T-ALL genes like MYC and, alone or in combinations with other chemotherapy drugs, suppress T-ALL cell survival in vitro and in pre-clinical models5,17,20.